FOR IMMEDIATE RELEASE:
SilcsBio is Selected by the NIH to
2021 BIO Digital’s Innovation Zone,
June 10-11 and 14-18
SilcsBio’s Sunhwan Jo to attend BIO Digital with focus on SilcsBio’s expertise in fragment-based drug design, MD simulations, and computational drug discovery
June 8, 2021, Baltimore, MD – SilcsBio, a technology company that develops and markets software and services for structure-based drug design, today announced the US National Institutes of Health (NIH) has designated SilcsBio for inclusion in its Innovation Zone at BIO Digital International Convention 2021, taking place virtually June 10-11 and 14-18.
The NIH’s Innovation Zone showcases NIH-funded companies, including SilcsBio, and their cutting-edge healthcare technologies.
The NIH’s Small Business Education and Entrepreneurial Development (SEED) program awarded SilcsBio with Innovation Zone status at BIO Digital, providing complimentary conference registration and the opportunity to showcase SilcsBio’s products and services for conference attendees via a 15-minute, pre-recorded presentation.
As part of this, SilcsBio’s Sunhwan Jo will present this recorded presentation beginning June 10. Jo’s presentation focuses on SilcsBio’s expertise in fragment-based drug design, MD simulations and computational drug discovery for pharmaceutical companies and pharmaceutical research organizations in need of computer-aided drug design services and support.
SilcsBio’s presentation can be viewed by registered BIO Digital attendees beginning June 10:
The NIH’s SEED program supports the NIH innovator community in their efforts to validate the potential health impacts of promising scientific discoveries and advance them into healthcare products that improve patient care and enhance health. SEED leads initiatives that develop these relationships and build opportunities for NIH innovators to further their product development efforts.
SilcsBio, LLC offers a platform technology that advances computational drug design applications through detailed molecular visualization and data mining. SilcsBio software and services span from protein surface mapping and analysis through lead drug optimization. The proprietary software unlocks hidden binding hotspots on target protein surfaces, and rapidly guides drug development. SILCS technology improves protein interaction predictions, permitting for the faster development of optimal and effective drug compounds and biologics therapeutics. Learn more: www.silcsbio.com
(410) 401-9794, ext. 701